A detailed history of Nuveen Asset Management, LLC transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 8,925,138 shares of ADMA stock, worth $173 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
8,925,138
Previous 10,461,376 14.68%
Holding current value
$173 Million
Previous $69 Million 44.52%
% of portfolio
0.03%
Previous 0.02%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$5.98 - $11.18 $9.19 Million - $17.2 Million
-1,536,238 Reduced 14.68%
8,925,138 $99.8 Million
Q1 2024

May 13, 2024

SELL
$4.4 - $6.74 $3.93 Million - $6.03 Million
-894,101 Reduced 7.87%
10,461,376 $69 Million
Q4 2023

Feb 14, 2024

BUY
$3.08 - $4.52 $2.06 Million - $3.03 Million
669,543 Added 6.27%
11,355,477 $51.3 Million
Q3 2023

Nov 14, 2023

BUY
$3.47 - $4.61 $7.38 Million - $9.8 Million
2,126,797 Added 24.85%
10,685,934 $38.3 Million
Q2 2023

Aug 14, 2023

SELL
$3.12 - $4.22 $1.48 Million - $2 Million
-473,176 Reduced 5.24%
8,559,137 $31.6 Million
Q1 2023

May 15, 2023

BUY
$3.01 - $3.87 $4.45 Million - $5.73 Million
1,479,806 Added 19.59%
9,032,313 $29.9 Million
Q4 2022

Feb 14, 2023

SELL
$2.47 - $3.88 $2.84 Million - $4.47 Million
-1,151,226 Reduced 13.23%
7,552,507 $29.3 Million
Q3 2022

Nov 14, 2022

BUY
$2.03 - $2.86 $3.13 Million - $4.41 Million
1,541,544 Added 21.52%
8,703,733 $21.2 Million
Q2 2022

Aug 15, 2022

SELL
$1.43 - $2.2 $618,833 - $952,052
-432,751 Reduced 5.7%
7,162,189 $14.2 Million
Q1 2022

May 16, 2022

SELL
$1.28 - $1.83 $3.86 Million - $5.52 Million
-3,017,660 Reduced 28.43%
7,594,940 $11.8 Million
Q4 2021

Feb 14, 2022

BUY
$1.09 - $1.66 $4.06 Million - $6.19 Million
3,727,960 Added 54.15%
10,612,600 $15 Million
Q3 2021

Nov 12, 2021

BUY
$1.13 - $1.65 $1.11 Million - $1.62 Million
980,981 Added 16.62%
6,884,640 $7.78 Million
Q2 2021

Aug 16, 2021

SELL
$1.51 - $2.07 $1.29 Million - $1.77 Million
-855,303 Reduced 12.65%
5,903,659 $9.45 Million
Q1 2021

May 17, 2021

BUY
$1.67 - $2.95 $10.9 Million - $19.2 Million
6,502,025 Added 2530.59%
6,758,962 $11.9 Million
Q4 2020

Feb 16, 2021

BUY
$1.8 - $2.56 $2,532 - $3,601
1,407 Added 0.55%
256,937 $501,000
Q3 2020

Nov 16, 2020

SELL
$2.04 - $3.74 $243,196 - $445,860
-119,214 Reduced 31.81%
255,530 $611,000
Q2 2020

Aug 14, 2020

SELL
$2.42 - $3.29 $933,713 - $1.27 Million
-385,832 Reduced 50.73%
374,744 $1.1 Million
Q1 2020

May 14, 2020

BUY
$1.5 - $4.59 $722,814 - $2.21 Million
481,876 Added 172.9%
760,576 $2.19 Million
Q4 2019

Feb 14, 2020

BUY
$3.89 - $5.15 $563,711 - $746,301
144,913 Added 108.32%
278,700 $1.12 Million
Q3 2019

Nov 14, 2019

BUY
$3.19 - $5.39 $206,370 - $348,695
64,693 Added 93.63%
133,787 $595,000
Q2 2019

Aug 15, 2019

BUY
$3.52 - $5.24 $243,210 - $362,052
69,094 New
69,094 $268,000

Others Institutions Holding ADMA

About ADMA BIOLOGICS, INC.


  • Ticker ADMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 196,356,992
  • Market Cap $3.81B
  • Description
  • ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...
More about ADMA
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.